-
1دورية أكاديمية
المؤلفون: Nicole C. Gavin, Tricia M. Kleidon, Emily Larsen, Catherine O’Brien, Amanda Ullman, Sarah Northfield, Gabor Mihala, Naomi Runnegar, Nicole Marsh, Claire M. Rickard
المصدر: Trials, Vol 21, Iss 1, Pp 1-11 (2020)
مصطلحات موضوعية: Feasibility, Hydrophobic polyurethane, Peripherally inserted central catheter (PICC), PICC failure, Pilot randomised controlled trial, Polyurethane, Medicine (General), R5-920
الوصف: Abstract Background To evaluate the feasibility of an efficacy trial comparing a hydrophobic polyurethane peripherally inserted central catheter (PICC) with a standard polyurethane PICC. Methods This pilot randomised controlled trial (RCT) was conducted between May 2017 and February 2018. Adult participants (n = 111) were assigned to hydrophobic polyurethane PICC with proximal valve (intervention) or a polyurethane PICC with external clamp (standard care). Primary outcome was trial feasibility including PICC failure. Secondary outcomes were central line-associated bloodstream infection, local infection, occlusion, thrombosis, fracture and dislodgement, phlebitis, local or systemic allergic reaction, and PICC dwell time. Results All feasibility outcomes were achieved, apart from eligibility criteria. In total, 338 patients were screened, 138 were eligible (41%), and of these 111 were randomised (80%). Patients received the allocated PICC in 106 (95%) insertions. No patients withdrew from the study and there was no missing data. PICC failure was 24% (13/55) in the intervention group and 22% (12/55) in the standard care group (p = 0.820). PICC failure per 1000 PICC days was 16.3 in the intervention group and 18.4 in the control group (p = 0.755). The average dwell time was 12 days in the intervention and 8 days in the control group. Conclusions This study demonstrates the feasibility of an efficacy trial of PICC materials in an adult population, once adjustments were made to include not only in-patients, but also patients being discharged to the Hospital in the Home service. Trial registration Australia and New Zealand Clinical Trials Registry ACTRN12616001578493 . Prospectively registered on 16 November 2016. The trial protocol was published a priori (Kleidon et al., Vasc Access 3:15–21, 2017).
وصف الملف: electronic resource
-
2
المؤلفون: Elise Button, Magnolia Cardona, Kathryn Huntley, Nicole C. Gavin, Thomas W. LeBlanc, Avalon Olsen, Michael Smith, Patsy Yates
المصدر: Journal of Palliative Medicine. 25:1386-1397
مصطلحات موضوعية: Death, Terminal Care, Cross-Sectional Studies, Anesthesiology and Pain Medicine, Hematologic Neoplasms, Humans, Patient Preference, General Medicine, Middle Aged, General Nursing
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e96efc72bcf9c5382f0662b20433329
https://doi.org/10.1089/jpm.2021.0490 -
3
مصطلحات موضوعية: surgical procedures, operative, nervous system, immune system diseases, hemic and lymphatic diseases
الوصف: PurposeOral mucositis and taste disturbance are common complications during haematopoietic stem cell transplantation (HSCT). This study aimed to review the incidence of severe mucositis and taste disturbance in patients undergoing different HSCT regimens. MethodsThis single-centre retrospective study reviewed daily oral assessment for 467 consecutive patients who underwent different transplant regimens for matched unrelated or related allogeneic HSCT with post-transplant methotrexate, haploidentical or mismatched HSCT with post-transplant cyclophosphamide (PTCy), or autologous HSCT. Oral care and cryotherapy with melphalan were used. Patient demographic data, oral mucositis WHO grade, taste disturbance, use of total parenteral nutrition (TPN) and patient-controlled analgesia (PCA) were collected. ResultsGrade 3-4 oral mucositis was common in myeloablative total body irradiation (TBI) based regimens cyclophosphamide/ TBI (CyTBI) (71%) and fludarabine/ TBI (FluTBI) with PTCy (46%), as well as reduced intensity fludarabine/ melphalan (FluMel) (43%) and carmustine/ etoposide/ cytarabine/ melphalan (BEAM) autologous HSCT (41%). In contrast, Grade 3-4 oral mucositis was less common in reduced intensity haploidentical regimen melphalan/ fludarabine/ TBI with PTCy (19%), all non-myeloablative regimens (0-9%) and high dose melphalan autologous HSCT (26%). TPN and PCA use were correlated to oral mucositis severity. Taste disturbance was common regardless of the regimens (89%, range 71-95%). ConclusionsSevere oral mucositis was associated with myeloablative TBI, methotrexate and melphalan in combination with methotrexate and in BEAM. Use of PTCy was preferable over methotrexate to prevent oral mucositis.
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::8f249bfbce982a9e2cacc8bcf0d54b3f
https://doi.org/10.21203/rs.3.rs-1313036/v1 -
4
المصدر: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 30(11)
مصطلحات موضوعية: Stomatitis, Methotrexate, Transplantation Conditioning, Oncology, Incidence, Hematopoietic Stem Cell Transplantation, Humans, Melphalan, Cyclophosphamide, Retrospective Studies
الوصف: Purpose Oral mucositis is a common complication during haematopoietic stem cell transplantation (HSCT). This study aimed to assess the incidence of severe mucositis in patients undergoing different HSCT regimens. Methods This single-centre retrospective study reviewed daily oral assessment for 467 consecutive patients who underwent different transplant regimens for matched unrelated or related allogeneic HSCT with post-transplant methotrexate, haploidentical or mismatched HSCT with post-transplant cyclophosphamide (PTCy), or autologous HSCT. Oral care and cryotherapy with melphalan were used. Patient demographic data, oral mucositis WHO grade, use of total parenteral nutrition (TPN) and patient-controlled analgesia (PCA) were collected. Results Grade 3–4 oral mucositis was common in myeloablative total body irradiation (TBI)-based regimens cyclophosphamide/ TBI (CyTBI) (71%) and fludarabine/ TBI (FluTBI) with PTCy (46%), as well as reduced-intensity fludarabine/melphalan (FluMel) (43%) and carmustine/etoposide/cytarabine/melphalan (BEAM) autologous HSCT (41%). In contrast, grade 3–4 oral mucositis was less common in reduced-intensity haploidentical regimen melphalan/fludarabine/TBI with PTCy (19%), all non-myeloablative regimens (0–9%) and high-dose melphalan autologous HSCT (26%). TPN and PCA use were correlated to oral mucositis severity. Conclusions Severe oral mucositis was associated with myeloablative TBI, methotrexate and melphalan in combination with methotrexate and in BEAM. Use of PTCy was preferable over methotrexate to prevent oral mucositis.
-
5
Full Text Finder